Endoscopic Sleeve Gastroplasty (ESG) Is a Reproducible and Effective Endoscopic Bariatric Therapy Suitable for Widespread Clinical Adoption: a Large, International Multicenter Study
| Autor: | Lawrence J. Cheskin, Erik B Wilson, Angielyn R Rivera, Anthony N. Kalloo, Adrian Sartoretto, Mouen A. Khashab, Lea Fayad, Margo Dunlap, Christine Hill, Zhixian Sui, George Marinos, Vivek Kumbhari |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Gastroplasty Endocrinology Diabetes and Metabolism Excess weight 030209 endocrinology & metabolism Body weight Body Mass Index 03 medical and health sciences 0302 clinical medicine Weight loss Weight Loss Medicine Humans Obesity Adverse effect Retrospective Studies Nutrition and Dietetics business.industry Australia Reproducibility of Results Total body Endoscopy Middle Aged medicine.disease Surgery Obesity Morbid Treatment Outcome Multicenter study 030211 gastroenterology & hepatology Female medicine.symptom business Body mass index |
| Zdroj: | Obesity surgery. 28(7) |
| ISSN: | 1708-0428 |
| Popis: | Endoscopic sleeve gastroplasty (ESG), an incisionless endoscopic bariatric procedure, has shown impressive results in case series. This study examines the reproducibility, efficacy, and safety in three centers across two countries, and identifies key determinants for procedural success. Patients who underwent ESG between February 2016 and May 2017 at one of three centers (Australia and USA) were retrospectively analyzed. All procedures were performed on an outpatient basis using the Apollo OverStitch device (Apollo Endosurgery, Austin, TX). Primary outcomes included absolute weight loss (ΔWeight, kg), change in body mass index (∆BMI, in kg/m2), total body weight loss (TBWL, %), excess weight loss (EWL, in %), and immediate and delayed adverse events. In total, 112 consecutive patients (male 31%, age 45.1 ± 11.7 years, baseline BMI 37.9 ± 6.7 kg/m2) underwent ESG. At 1, 3, and 6 months, Δweight was 9.0 ± 4.6 kg (TBWL 8.4 ± 4.1%), 12.9 ± 6.4 kg (TBWL 11.9 ± 4.5%), and 16.4 ± 10.7 kg (TBWL 14.9 ± 6.1%), respectively. The proportion of patients who attained greater than 10% TBWL and 25% EWL was 62.2 and 78.0% at 3 months post-ESG and 81.0 and 86.5% at 6 months post-ESG. Weight loss was similar between the three centers. Multivariable analysis showed that male sex, greater baseline body weight, and lack of prior endoscopic bariatric therapy were predictors of greater Δweight at 6 months. Three (2.7%) severe adverse events were observed. ESG is an effective, reproducible, and safe weight loss therapy that is suitable for widespread clinical adoption. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink